This collection, categorized by area of interest, is intended to provide convenient and quick access to research on a wide-spectrum of topics related to breast and ovarian cancer risk stratification and management, as well as risk-reduction and early detection.
Chemoprevention for High-Risk Patients
Patient-Reported Symptoms and Quality of Life During Treatment with Tamoxifen or Raloxifene for Breast Cancer Prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Land SR, Wickerham DL, Constantino JP, et al. JAMA. June 21, 2006. 295(23): 2742-51.
Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study
Antoniou AC, Rookus M, Andrieu N, et al. Cancer Epidemiol Biomarkers Prev. February 2009. 18(2): 601–10.
Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention
Nichols HB, DeRoo LA, Scharf DR, Sandler DP. J Natl Cancer Inst. 2015. 107(1): dju354.
The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data from a Randomized Breast Cancer Risk Reduction Trial
Vogel V, Constantino JP, Wickerham DL, Cronin WM, Wolmark N. Clinical Breast Cancer. June 2002. 3(2): 153-159.
Tamoxifen Versus Raloxifene in the Prevention of Breast Cancer
Wickerham DL. Eur J Cancer. 2002. 38 (Suppl 6): S20-S21.
Increasing Black: White disparities in breast cancer mortality in the 50 largest cities in the United States
Hunt BR, Whitman S, Hurlbert MS. Cancer Epidemiol. April 2014; 38(2): 118-23.
Parity, Lactation, and Breast Cancer Subtypes in African American Women: Results from the AMBER Consortium
Palmer JR, Viscidi E, Troester MA, et al. J Natl Cancer Inst. 2014. 106(10): dju237doi: 10.1093/jnci/dju237
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years
Malone KE, Daling, JR, Doody DR, et al. Cancer Res. August 15, 2006; 66; 8297.
Epidemiology of Breast Cancer
Breast Cancer Facts & Figures 2011-2012
American Cancer Society, Cancer.org
CDC Vital Signs: Breast Cancer
Centers for Disease Control, CDC.gov
CDC Vital Signs: Ovarian Cancer
Centers for Disease Control, CDC.gov
NCI Cancer Topics: Breast Cancer
National Cancer Institutes. National Institutes of Health, Cancer.gov
NCI Cancer Topics: Ovarian Cancer
National Cancer Institutes. National Institutes of Health, Cancer.gov
SEER Stat Fact Sheets: Breast Cancer
SEER, National Cancer Institute, Cancer.gov
SEER Stat Fact Sheets: Ovarian Cancer
SEER, National Cancer Institute, Cancer.gov
Familial Ovarian Cancer
Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families
Kauff ND, Mitra, N, Robson ME, et al. J Natl Cancer Inst. 97(18): September 21, 2005; 97(18): 1382-4.
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
Antoniou A, Pharoah PDP, Narod S, et al. Am J Hum Genet. 2003; 72: 1117-1130.
Breast and Ovarian Cancer Incidence in BRCA1-Mutation Carriers
Easton, DF, Ford D, Bishop DT. Am J Hum Genet. January 1995; 56(1): 265–271.
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King MC, Marks JK, Mandell JB. Science. October 24, 2003: 643-646.
BRCA1 and BRCA2: Cancer Risk and Genetic Testing
National Cancer Institute. National Institutes of Health, Cancer.gov
BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing Recommendation Statement
Characteristics Associated with Genetic Counseling Referral and BRCA1/2 Testing Among Women in a Large Integrated Health System
Bellcross CA, Peipins LA, McCarty FA, et al. Genet Med. January 2015; 17(1): 43-50.
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families.
Ford D, Easton DF, Stratton M, et al. Am J Hum Genet. March 1998; 62(3): 676-689.
Genetic Testing by Cancer Site: Breast
Shannon KM, Chittenden, A. Cancer J. July-August 2012; 18(4): 310-9.
Genetic Testing by Cancer Site: Ovary
Weissman SM, Weiss SM, Newlin, AC. Cancer J. July-August 2012; 18(4): 320-7.
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer
Pruthi S, Gostout BS, Lindor NM. Mayo Clin Proc. December 2010; 85(12): 1111-1120.
Patient-Reported Hereditary Breast and Ovarian Cancer in a Primary Care Practice
Quillin JM, Krist A, Gyure M, et al. J Community Genet. April 2014; 5(2): 179–183.
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer
Whittemore AS, Gong G, Itnyre J. Am J Hum Genet. March 1997; 60(3): 496-504.
Risk Assessment Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation
Nelson HD, Fu R, Goddard K et al. Systematic Review to Update the USPSTF Recommendation. December 2013;
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 Among Ashkenazi Jews
Struewing JP, Hartge P, Wacholder S, et al. N Engl J Med. 1997; 336: 1401-1408.
Risks of Cancer in BRCA1-Mutation Carriers
Ford D. Lancet. 1994; 343: 692-695.
Lifestyle Modification for Reducing Risk
Alcohol, Tobacco and Breast Cancer – Collaborative Reanalysis of Individual Data From 53 Epidemiological Studies, Including 58,515 Women with Breast Cancer and 95,067 Women Without the Disease
Collaborative Group on Hormonal Factors in Breast Cancer. Br J Cancer. November 18, 2002; 87(11): 1234-45
Breast Cancer Prevention Starts in Childhood
Brookes L, Coldlitz GA. Medscape. December 2014.
Breast Self-Awareness: The Evidence Behind the Euphemism
Mark K, Temkin SM, Terplan, M. Obstet Gynecol. April 2014; 123(4): 734–736.
Folate and Risk of Breast Cancer – A Meta-analysis
Larsson SC, Giovannucci E, Wolk, Alicja. J Natl Cancer Inst. January 3, 2007; 99(1): 64-76.
Effects of the Exercise-Induced Myokine Irisin on Malignant and Non-Malignant Breast Epithelial Cell Behavior In Vitro
Gannon NP, Vaughn RA, Garcia-Smith R, Bisoffi M., Trujillo KA. Int J Cancer. February 25, 2015. 136(4):E 197-202.
Effects of Menarche and Menopause on Breast Cancer Risk: Meta-analysis Findings
Stenger M. ASCO Post. April 15, 2013. 4(6).
Separating the Baby From the Bath Water: Breast Self-Awareness and Breast Self-Examination
Pearlman, MD. Obstet Gynecol. April 2014. 123(4): 731-733.
Smoking and Mortality — Beyond Established Causes
Carter BD, Abnet CC, Feskanich D, et al. N Engl J Med. February 12, 2015; 372:631-640.
Timing of Menarche and First Full-Term Birth in Relation to Breast Cancer Risk
Li CI, Malone KE, Daling JR, et al. Am J Epidemiol. 2008; 167(2): 230-239.
Why Does Eating Red Meat Elevate Breast Cancer Risk, Especially for Young Women on the Pill?
Kobayashi L. Public Health Perspectives, PLOS Blogs. November 5, 2014.
Association of Estrogen and Progestin Potency of Oral Contraceptives with Ovarian Carcinoma Risk
Lurie G. Obstet Gynecol. March 2007; 109(3): 597-607.
Ovarian Cancer and Oral Contraceptives: Collaborative Reanalysis of Data from 45 Epidemiological Studies Including 23,257 Women with Ovarian Cancer and 87,303 Controls
Collaborative Group on Epidemiological Studies of Ovarian Cancer. Lancet. January 2008; 371(9609): 303-314.
Other Health Risks for High-Risk Patients
Million Women Study
Women’s Health Initiative
Physician Knowledge, Training and Practice
Awareness and Utilization of BRCA1/2 Testing Among U.S. Primary Care Physicians
Bellcross CA, Kolor K, Goddard KAB, Coates RJ, Reyes M, Khoury MJ. Am J Prev Med. January 2011. 40(1): 61-66
Does Knowledge About the Genetics of Breast Cancer Differ Between Nongeneticist Physicians Who Do or Do Not Discuss or Order BRCA Testing?
Doksum T, Bernhardt BA, Holtzman NA. Genet Med. 2003. 5: 99-105.
Genetic Testing for Susceptibility to Breast and Ovarian Cancer: Evaluating the Impact of a Direct-to-Consumer Marketing Campaign on Physicians’ Knowledge and Practices
Myers MF, Chang MH, Jorgensen C, et al. Genet Med. 2006. 8:361-370.
Gynecologists’ Training, Knowledge, and Experiences in Genetics: A Survey
Wilkins-Haug, L, Hill L, Power ML, Holzman GB, Schulkin J. Obstet Gynecol. March 2000. 95(3): 421-424.
Hereditary Breast/Ovarian and Colorectal Cancer Genetics Knowledge in a National Sample of US Physicians
Wideroff, L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN. J Med Genet. 2005. 42(10): 749-755.
Obstetrician-Gynecologists’ Knowledge and Opinions About the United States Preventive Services Task Force (USPSTF) Committee, the Women’s Health Amendment, and the Affordable Care Act: National Study After the Release of the USPSTF 2009 Breast Cancer Screening Recommendation Statement
Anderson, BL, Urban RR, Pearlman M, Schulkin J. Preventive Medicine. February 2014. 59(1): 79-82.
A Survey of OB/GYN Physicians’ Training & Current Practice Patterns in Breast Care
Pearlman MD, Anderson BS, Bell AV, Griffin JL, Shulkin J, De Vries R. Breast J. November 2012. 18(6): 634-636.
Screening and Risk Reduction for Increased-Risk Patients (Moderate Risk for Breast Cancer)
Breast Cancer Risk-Assessment Models
Gareth D, Evans R, Howell A. Breast Cancer Research. 2007. 9(5): 213.
Breast Cancer Risks in Women with a Family History of Breast or Ovarian Cancer Who Have Tested Negative for a BRCA1 or BRCA2 Mutation
Metcalfe KA, Finch A, Poll A, et al. Br J Cancer. 2009: 100(2): 421-5.
Effectiveness of Alternating Mammography and Magnetic Resonance Imaging for Screening Women with Deleterious BRCA Mutations at High Risk of Breast Cancer
Le-Petross HT, Whitman GJ, Atchley DP, et al. Cancer. September 1, 2011; 117(17): 3900-3907.
Exposure to Diagnostic Radiation and Risk of Breast Cancer Among Carriers of BRCA1/2 Mutations: Retrospective Cohort Study (GENE-RAD-RISK)
Pijpe A, Andrieu N, Easton DF, et al. BMJ. September 6, 2012; 345:e5660.
Prevention and Management of Hereditary Breast Cancer
Narod SA, Offit K. J Clin Onco. March 10, 2005; 23(8): 1656-63.
Relevance and Efficacy of Breast Cancer Screening in BRCA1 and BRCA2 Mutation Carriers Above 60 Years: a National Cohort Study
Saadatmand S, Vos JR, Hooning MJ, et al. Int J Cancer. December 15, 2014. 135(12): 2940-9.
Risk Management Options Elected by Women after Testing Positive for a BRCA Mutation
Garcia C., Wendt J, Lyon L et al. Gynecol Oncol. February 2014; 132(2): 428-33.
Routine Screening for Hereditary Breast and Ovarian Cancer Recommended
ACOG Practice Bulletin. March 23, 2009.
Short-term Outcomes of the Implementation of a Computer-Based Breast Cancer Risk Assessment Program During Screening Mammography
Ray D, Grumet S, Lagmay-Fuentes P, et al. J Community Support Oncol. June 2014; 12(6): 209-11.
Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast Examination
Warner E, Plewes DB, Hill KA, et al. JAMA. September 15, 2004; 292(11): 1317-25.
A Systematic Review of the Effectiveness of Magnetic Resonance Imaging (MRI) As an Addition to Mammography and Ultrasound in Screening Young Women at High Risk for Breast Cancer
Lord SJ, Lei W, Craft P, et al. Eur J Cancer. September 2007; 43(13): 1905-17.
Screening/Mammography for Average-Risk Patients
Breast Cancer: Screening Recommendations
US Preventive Services Task Force. November 2009. USPreventiveServicesTaskForce.org
Likelihood Ratios for Modern Screening Mammography: Risk of Breast Cancer Based on Age and Mammographic Interpretation
Kerjkowske K, Grady D, Barclay J, Sickles EA, Ernster V. JAMA. July 3, 1996; 276(1): 39-43.
Surgical Risk Reduction for High-Risk Patients
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Domchek SM. Friebel, TM, Singer CF, et al. JAMA. September 2010; 304(9): 967-975.
Bilateral Prophlactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
Rebbeck TR, Friebel T, Lynch HT, et al. J Clin Oncol. March 15, 2004; 22(6): 1055–1062.
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer H, van Geel B, van Putten WLJ, et al. N Engl J Med. July 19, 2001; 345(3): 159–164.
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck TR, Levin AM, Eisen A, et al. J Natl Cancer Inst. 1999; 91(17): 1475–1479.
Defining Cancer Risks for BRCA Germline Mutation Carriers: Implications for Surgical Prophylaxis
Karlan. Gynecol Oncol. February 2004. 92 (2): 519-520.
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann LC, Sellers TA, Schaid DJ, et al. J Natl Cancer Inst. November 7, 2001; 93(21): 1633–1637.
Ideal Risk Reduction Management for Women With BRCA Gene Mutations: Still Not There Yet
Pearlman, MD. Obstet Gynecol. January 2013. 121(1): 4-6.
Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis
Yates MS, Meyer LA, Deavers MT, et al. Cancer Prev Res. March 2011; 4: 463.
Molecular Evidence Linking Primary Cancer of the Fallopian Tube to BRCA1 Germline Mutations
Zweemer RP, van Diest PH, Verheijen RH, et al. Gynecol Oncol. January 2000; 76(1): 45-50.
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck TR, Lynch HT, Neuhausen SL, et al. N Engl J Med. 2002; 346(21): 1616–1622.
Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers
Kwon JS, Tinker A, Pansegrau G et al. Obstet Gynecol. January 2013; 121(1): 14-24.
Prophylactic Salpingectomy with Delayed Oophorectomy
M.D. Anderson Cancer Center. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (S). 2000-August 2014. NLM Identifier: NCT01907789.
A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study
Greene MH, Piedmonte M, Alberts D, et al. Cancer Epidemol Biomarker Prev. March 2008; 17(3): 594-604.
Risk of Developing Uterine Corpus Cancer (Ut Ca) Following Risk-Reducing Salpingo-Oophorectomy (RRSO) in Women with BRCA Mutations
Shu, CA, Kauff, N.D., et al. SGO, March 2014. Abstr LBA5.
The Risk of Endometrial Cancer in Women with BRCA1 and BRCA2 Mutations. A Prospective Study
Beiner ME, Finch A, Rosen B, et al. Gynecol Oncol. January 2007; 104(1): 7-10.
Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
Kauff ND, Domchek SM, Friebel TM, et al. J Clin Oncol. March 2008. 26(8):1331-7.
Tubal Ligation and the Risk of Ovarian Cancer: Review and Meta-Analysis
Cibula D, Widschwendter M, Majek O, Dusek L. Hum. Reprod. Update 2011; 17(1): 55-67.
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
Narod SA, Sun P, Ghadirian P, et al. Lancet. May 12, 2001; 357(9267): 1467-70.